Search Results - s

1442 Results

Sort By:

Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity

Cancer immunotherapy has transformed treatment for some patients, but many tumors still do not respond well to current options, including checkpoint inhibitors. Researchers at NIAID’s Laboratory of Immune System Biology (LISB) have developed new antibodies designed to help the immune system fight tumors. These lab-made antibodies, called pan-anti-HLA...

Published: 7/16/2026 | Updated: 7/16/2026 | Inventor(s): David Margulies, Abir Panda, Ethan Shevach, Kannan Natarajan, Patricia Korty

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought, TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease

MC38 B2m KO Cell Line

Summary: The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research tool provides an opportunity to study checkpoint-refractory tumors and evaluate alternative...

Published: 7/14/2026 | Updated: 7/14/2026 | Inventor(s): Jeffrey Schlom, Duane Hamilton

Keywords(s):

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials

Quantitative Particle Identification (QPID) Digital Autoradiography System

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities. Description of Technology: Autoradiography is a photographic process that exposes a medium, sensitive to radiation, to a sample...

Published: 7/9/2026 | Updated: 7/8/2026 | Inventor(s): Stephen Adler

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Radiology, Application > Non-Medical Devices

RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS). This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition...

Published: 6/24/2026 | Updated: 6/24/2026 | Inventor(s): Paul Sieving, Yong Zeng, Ronald Bush

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases

Gene Therapy for Leber Congenital Amaurosis

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations. This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases

Innovative Gene Therapy for Retinal Diseases

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases. This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Susan Gentleman, Thomas Redmond

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Virus/Bacteria, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases

Advanced Gene Editing Technology for Therapeutic Applications

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications. This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited,...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Ruchi Sharma, Kapil Bharti

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Sequences, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases

Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases. This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1),...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Paul Sieving, Alaknanda MIshra, Vijayasarathy Camasamudram, Lisa Wei

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases

Immunosuppressive Exosomes for Treating Autoimmune Diseases

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases. This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Minkyung Kang, Charles Egwuagu

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Carriers/Adjuvants, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Ophthalmology

Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma. This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Myungkuk Joe

Keywords(s):

1 2 3 4 5 6 7 8 9 10 ...